Literature DB >> 16625848

An overview of the epidemiology and genetics of acromegaly.

A F Daly1, P Petrossians, A Beckers.   

Abstract

Historical data indicate that pituitary tumors represent 10% of intracranial tumors, while adenomas are noted in approximately 14-23% of normal subjects on autopsy or magnetic resonance imaging (MRI). About 2.5% of these tumors stain positive for GH in histopathologic studies. In contrast, the prevalence of clinically diagnosed acromegaly is lower at 36-69 per million population. Ongoing studies indicate that the actual prevalence of acromegaly in the community may be higher than previous epidemiologic data suggest. Acromegaly can occur both sporadically and in the setting of familial conditions, such as multiple endocrine neoplasia type 1 (MEN1) and Carney complex (CNC). Isolated familial somatotropinoma has been described and newer data suggest that acromegaly may also occur in non-MEN1/CNC families in combination with other pituitary tumor phenotypes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16625848

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  9 in total

1.  Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center.

Authors:  Susanna Bacigaluppi; Federico Gatto; Pasquale Anania; Nicola Luigi Bragazzi; Diego Criminelli Rossi; Giulia Benvegnu; Elena Nazzari; Renato Spaziante; Massimo Giusti; Diego Ferone; Gianluigi Zona
Journal:  Endocrine       Date:  2015-05-17       Impact factor: 3.633

Review 2.  Polycythemia as rare secondary direct manifestation of acromegaly: management and single-centre epidemiological data.

Authors:  Gabriele Zoppoli; Federico Bianchi; Andrea Bruzzone; Alessandro Calvia; Caterina Oneto; Caterina Passalia; Enrico Balleari; Davide Bedognetti; Elena Ponomareva; Elena Nazzari; Lara Castelletti; Lucio Castellan; Francesco Minuto; Riccardo Ghio; Diego Ferone
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

3.  The problem of unrecognized acromegaly: surgeries patients undergo prior to diagnosis of acromegaly.

Authors:  F E Keskin; D O Yetkin; H M Ozkaya; O Haliloglu; S Sadri; N Gazioglu; N Tanrıover; H Ak; E Hatipoglu; P Kadıoglu
Journal:  J Endocrinol Invest       Date:  2015-02-26       Impact factor: 4.256

4.  Psychosocial morbidity in acromegaly: a study from India.

Authors:  Surendra Kumar Mattoo; Anil Kumar Bhansali; Nitin Gupta; Sandeep Grover; Ramma Malhotra
Journal:  Endocrine       Date:  2008-10-25       Impact factor: 3.633

5.  Management of acromegaly.

Authors:  Vladimir Vasilev; Adrian Daly; Sabina Zacharieva; Albert Beckers
Journal:  F1000 Med Rep       Date:  2010-07-22

Review 6.  Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.

Authors:  Albert Beckers; Lauri A Aaltonen; Adrian F Daly; Auli Karhu
Journal:  Endocr Rev       Date:  2013-01-31       Impact factor: 19.871

7.  Diagnostic delay is associated with psychosocial impairment in acromegaly.

Authors:  Sonja Siegel; Christine Streetz-van der Werf; Jennifer S Schott; Kay Nolte; Wolfram Karges; Ilonka Kreitschmann-Andermahr
Journal:  Pituitary       Date:  2013-12       Impact factor: 4.107

8.  Acromegaly discovered during a routine out-patient surgical procedure: a case report.

Authors:  Chukwudi O Chiaghana; Julia M Bauerfeind; Cheri A Sulek; J Christopher Goldstein; Caleb A Awoniyi
Journal:  J Med Case Rep       Date:  2017-06-24

Review 9.  Need for improved monitoring in patients with acromegaly.

Authors:  Julie M Silverstein
Journal:  Endocr Connect       Date:  2015-09-17       Impact factor: 3.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.